Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03643159 · ClinicalTrials.gov registry record · Phase 4
A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder
A Phase 4 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT03643159 is a Phase 4 study that was terminated before completion, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 2 participants.
The verdict
NCT03643159, a Phase 4 study, was terminated before completion, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
The primary objective of this pragmatic clinical trial (Main Study) was to assess the difference between all-cause hospitalizations in participants using Abilify MyCite versus virtual matched controls. In addition, secondary and exploratory objectives were to assess medication adherence, healthcare utilization and costs, and patient-reported outcomes.
Interventions
- COMBINATION_PRODUCT Abilify MyCite - Digital Medicine System
- DRUG Aripiprazole or other oral antipsychotics
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2018-06-28 |
| Est. Completion | 2018-10-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03643159
The ClinicalTrials.gov registry entry for NCT03643159 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Abilify MyCite - Digital Medicine System is the first listed.
NCT03643159 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03643159 about?
NCT03643159 is a clinical study titled "A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder". The primary objective of this pragmatic clinical trial (Main Study) was to assess the difference between all-cause hospitalizations in participants using Abilify MyCite versus virtual matched controls. In addition, secondary and exploratory objectives were to assess medication adherence, healthcare ...
What is the current status of trial NCT03643159?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2018-06-28. Estimated completion is 2018-10-17.
What interventions are being tested in trial NCT03643159?
The interventions under investigation include: Abilify MyCite - Digital Medicine System (COMBINATION_PRODUCT), Aripiprazole or other oral antipsychotics (DRUG).
Who is sponsoring clinical trial NCT03643159?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.